ADVERTISEMENT
Regeneron Pharmaceuticals Inc., based in Greenburgh, and Paris-based Sanofi will announce details from four pivotal trials in their alirocumab clinical program Sunday at ESC Congress 2014 in Barcelona, the world’s largest cardiology meeting.
The pharmaceutical firms will announce the results from a long-term, double-blind study of 2,341-patients testing the safety and efficacy of alirocumab; a 720-patient, double-blind trial evaluating the long-term safety and efficacy of alirocumab compared with a combination of other drugs; and two trials involving a total of 738 patients with an inherited form of high cholesterol that compare the efficacy of the drug to a placebo.
Alirocumab is an investigational anti-cholesterol drug.
